tetano
Editor, Senior Moderator
Am J Transl Res
. 2024 Feb 15;16(2):681-689.
eCollection 2024. Monoclonal neutralizing antibodies against SARS-COV-2 S protein
Lin-Dong Cheng[SUP] 1 [/SUP], Ping Li[SUP] 2 [/SUP], Yan-Chen Lin[SUP] 1 [/SUP], Hui-Xiu Hu[SUP] 1 [/SUP], Ying Zhang[SUP] 1 [/SUP], Hou-Feng Li[SUP] 1 [/SUP], Jing Huang[SUP] 2 [/SUP], Li Tan[SUP] 3 [/SUP], Ning Ma[SUP] 4 [/SUP], Deng-Yun Xia[SUP] 5 [/SUP]
Affiliations
Novel coronavirus pneumonia, also known as coronavirus disease 2019 (COVID-19), is caused by sub-severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) infection. The spike (S) protein of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors widely expressed on the surface of human cells leading to life-threatening respiratory infections. A serious hazard to human health is posed by the lack of particular treatment medications for this virus infection. We advocate the creation of high-affinity antibodies using the receptor binding domain (RBD) of S protein as a specific antigenic epitope to develop a drug that can precisely target therapy COVID-19 because SARS-CoV-2 infection of the host cells is dependent on S protein binding to ACE2. Finally, we obtained high-affinity antibodies 14F4HL and 14E3HL that have high affinity with RBD and well-drug-forming properties, suitable for further humanization studies. Thus, monoclonal antibodies that neutralize the S protein were identified in our study, which may provide new insights for the development of COVID-19 therapeutic drugs.
Keywords: ACE2; COVID-19; SARS-CoV-2; hybridoma fusion; monoclonal antibody.
. 2024 Feb 15;16(2):681-689.
eCollection 2024. Monoclonal neutralizing antibodies against SARS-COV-2 S protein
Lin-Dong Cheng[SUP] 1 [/SUP], Ping Li[SUP] 2 [/SUP], Yan-Chen Lin[SUP] 1 [/SUP], Hui-Xiu Hu[SUP] 1 [/SUP], Ying Zhang[SUP] 1 [/SUP], Hou-Feng Li[SUP] 1 [/SUP], Jing Huang[SUP] 2 [/SUP], Li Tan[SUP] 3 [/SUP], Ning Ma[SUP] 4 [/SUP], Deng-Yun Xia[SUP] 5 [/SUP]
Affiliations
- PMID: 38463597
- PMCID: PMC10918147
Novel coronavirus pneumonia, also known as coronavirus disease 2019 (COVID-19), is caused by sub-severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) infection. The spike (S) protein of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors widely expressed on the surface of human cells leading to life-threatening respiratory infections. A serious hazard to human health is posed by the lack of particular treatment medications for this virus infection. We advocate the creation of high-affinity antibodies using the receptor binding domain (RBD) of S protein as a specific antigenic epitope to develop a drug that can precisely target therapy COVID-19 because SARS-CoV-2 infection of the host cells is dependent on S protein binding to ACE2. Finally, we obtained high-affinity antibodies 14F4HL and 14E3HL that have high affinity with RBD and well-drug-forming properties, suitable for further humanization studies. Thus, monoclonal antibodies that neutralize the S protein were identified in our study, which may provide new insights for the development of COVID-19 therapeutic drugs.
Keywords: ACE2; COVID-19; SARS-CoV-2; hybridoma fusion; monoclonal antibody.